At present BioLight has two clusters that focuse on Cancer Diagnostics and ophthalmic diseases. Additional clusters are in development at various planning stages.
Micromedic is a publicly traded company listed on the Tel Aviv Stock Exchange. The Company focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities (personalized medicine).
Read more >>
XLVision is BioLight’s wholly owned ophthalmic cluster.
XLVision currently has three technologies: a commercial laser-based device used to reduce intraocular pressure through glaucoma surgery without penetrating the eyeball; a multi-parameter, easy-to-read test to detect, select treatment and monitor dry eye syndrome and a long-term controlled-release drug-delivery implant platform with a first indication containing latanaprost, the most prescribed glaucoma drug.